APA

Patt Y. Z., Lee F., Liebmann J. E., Diamandidis D., Eckhardt S. G., Javle M., Justice G. R., Keiser W., Salvatore J. R., Bexon A. & Lin E. (20070927). Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. : American journal of clinical oncology.

Chicago

Patt Yehuda Z, Lee Fa-Chyi, Liebmann James E, Diamandidis Dimitrios, Eckhardt S Gail, Javle Milind, Justice Glen R, Keiser Wayne, Salvatore Joseph R, Bexon Alice and Lin Edward. 20070927. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. : American journal of clinical oncology.

Harvard

Patt Y. Z., Lee F., Liebmann J. E., Diamandidis D., Eckhardt S. G., Javle M., Justice G. R., Keiser W., Salvatore J. R., Bexon A. and Lin E. (20070927). Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. : American journal of clinical oncology.

MLA

Patt Yehuda Z, Lee Fa-Chyi, Liebmann James E, Diamandidis Dimitrios, Eckhardt S Gail, Javle Milind, Justice Glen R, Keiser Wayne, Salvatore Joseph R, Bexon Alice and Lin Edward. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. : American journal of clinical oncology. 20070927.